<DOC>
	<DOCNO>NCT00253422</DOCNO>
	<brief_summary>RATIONALE : Estrogen cause growth breast cancer cell . Hormone therapy use fulvestrant , anastrozole , exemestane may fight breast cancer block use estrogen tumor cell lower amount estrogen body make . It yet know whether give fulvestrant together anastrozole effective give fulvestrant together placebo exemestane alone treat breast cancer . PURPOSE : This randomized phase III trial study fulvestrant anastrozole see well work compare fulvestrant placebo exemestane alone treat postmenopausal woman locally advance metastatic breast cancer .</brief_summary>
	<brief_title>Fulvestrant With Without Anastrozole Exemestane Alone Treating Postmenopausal Women With Locally Advanced Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare progression-free survival postmenopausal woman estrogen receptor- and/or progesterone receptor-positive , locally advanced metastatic breast cancer relapse progressed prior treatment nonsteroidal aromatase inhibitor treat fulvestrant v without anastrozole v exemestane alone . Secondary - Compare objective complete response ( CR ) partial response ( PR ) rate duration response patient treat regimen . - Compare clinical benefit ( i.e. , 6-month CR , PR , stable disease ) rate duration clinical benefit patient treat regimen . - Compare time treatment failure patient treat regimen . - Compare overall survival patient treat regimen . - Compare tolerability regimens patient . OUTLINE : This randomize , partially double-blind placebo-controlled , multicenter study . Patients stratify accord set prior nonsteroidal aromatase-inhibitor therapy give ( adjuvant therapy v first-line therapy ) participate center . Patients randomize 1 3 treatment arm . - Arm I ( fulvestrant anastrozole ) : Patients receive fulvestrant intramuscularly ( IM ) day 1 , 15 , 29 monthly . Patients receive oral anastrozole daily . - Arm II ( fulvestrant placebo ) : Patients receive fulvestrant arm I oral placebo daily . - Arm III ( exemestane alone ) : Patients receive oral exemestane daily . In arm , treatment repeat every month absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically survival . PROJECTED ACCRUAL : A total 750 patient ( 250 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm adenocarcinoma breast Locally advance metastatic disease Metastatic disease must measurable evaluable Patients bone metastasis eligible provide evaluable site bone metastasis follow xray , MRI , CT scan Relapsed progressed prior treatment singleagent nonsteroidal aromatase inhibitor ( NSAI ) * , meet either follow criterion : NSAI give adjuvant therapy last ≥ 12 month Achieved objective complete response , partial response , stable disease last ≥ 6 month prior firstline therapy NSAI locally advance metastatic disease Chemotherapy part firstline therapy give initiation NSAI allow NOTE : *Patients require continue take NSAI begin study treatment . No rapidly progressive visceral disease ( i.e. , lymphangitis carcinomatosa diffuse hepatic involvement ) Hormone receptor status : Estrogen receptor ( ER ) and/or progesterone receptor positive tumor No ERunknown disease PATIENT CHARACTERISTICS : Sex Female Menopausal status Postmenopausal , define 1 follow criterion : Age 60 Age 45 59 AND ≥ 12 month since last menstrual period prior hysterectomy Any age prior bilateral oophorectomy Performance status WHO 02 Life expectancy More 3 month Hematopoietic Neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 No thrombocytopenia Hemoglobin ≥ 10 g/dL Hepatic AST ALT ≤ 2.5 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 5 time ULN ( unless due bone metastasis ) No liver disease Renal Creatinine &lt; 1.97 mg/dL Other No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Chemotherapy See Disease Characteristics Prior neoadjuvant adjuvant chemotherapy allow Endocrine therapy See Disease Characteristics Prior tamoxifen neoadjuvant adjuvant therapy allow No systemic corticosteroid last &gt; 15 day within past 4 week Other More 4 week since prior investigational drug Concurrent bisphosphonates bone metastasis allow provided bisphosphonate therapy establish ≥ 6 month Concurrent initiation bisphosphonate allow provided patient soft tissue visceral metastasis measurable evaluable target lesion No concurrent anticoagulant therapy No concurrent unlicensed noncancer investigational agent</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
</DOC>